Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Biliary tract cancers that progress after first line treatment can be difficult to treat.
There is a great need for an effective, tolerable, easy to administer second-line regimen.
Previous early phase studies demonstrated that the combination of two chemotherapy drugs,
irinotecan and capecitabine had activity in this setting. The goal of this study is to
determine whether this drug combination, as a second-line treatment, can improve progression
free survival in patients with biliary tract cancers.